July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Biomarkers and endpoints for dry AMD trials
Author Affiliations & Notes
  • Srinivas R Sadda
    Doheny Eye Institute, Los Angeles, California, United States
    Ophthalmology, University of California - Los Angeles, Los Angeles, California, United States
  • Footnotes
    Commercial Relationships   Srinivas Sadda, Allergan (C), Amgen (C), Carl Zeiss Meditec (F), Centervue (C), Genentech (C), Heidelberg (C), NightStarRx (C), Novartis (C), Optos (C), Thrombogenics (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 991. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Srinivas R Sadda; Biomarkers and endpoints for dry AMD trials. Invest. Ophthalmol. Vis. Sci. 2019;60(9):991.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Presentation Description : Advances in OCT and OCT image analysis have yielded opportunities to better track the progression and evolution of non-neovascular age-related macular degeneration (AMD). This has allowed the indentification of novel OCT risk factors for progression of AMD which may create a path forward for early intervention trials. In addition, the development of OCT-based definitions for atrophy have created an opportunity for OCT to be used as a modality for assessing the late stages of dry AMD (atrophy). These new OCT-based approaches will be reviewed in this presentation.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.